Campus Units

Animal Science

Document Type

Article

Publication Version

Published Version

Publication Date

10-2020

Journal or Book Title

Biomedicine & Pharmacotherapy

Volume

130

First Page

110530

DOI

10.1016/j.biopha.2020.110530

Abstract

Sorafenib (SR) is one of the most potent UGT (1A1, 1A9) inhibitors (in in vitro tests). The inhibition of UGT1A1 may cause hyperbilirubinaemia, whereas the inhibition of UGT1A9 and 1A1 may result in drug-drug interactions (DDIs). Tapentadol (TAP) is a synthetic μ-opioid agonist and is used to treat moderate to severe acute pain. Tapentadol is highly glucuronidated by the UGT1A9 and UGT2B7 isoenzymes. The aim of the study was to assess the DDI between SR and TAP.

Wistar rats were divided into three groups, with eight animals in each. The rats were orally treated with SR (100 mg/kg) or TAP (4.64 mg/kg) or in combination with 100 mg/kg SOR and 4.64 TAP mg/kg. The concentrations of SR and sorafenib N-oxide, TAP and tapentadol glucuronide were respectively measured by means of high-performance liquid chromatography (HPLC) with ultraviolet detection and by means of ultra-performance liquid chromatography-tandem mass spectrometry.

The co-administration of TAP with SR caused TAP maximum plasma concentration (Cmax) to increase 5.3-fold whereas its area under the plasma concentration-time curve (AUC0-∞) increased 1.5-fold. The tapentadol glucuronide Cmax increased 5.3-fold and whereas its AUC0-∞ increased 2.0-fold. The tapentadol glucuronide/TAP AUC0–∞ ratio increased 1.4-fold (p = 0.0118). TAP also increased SR Cmax 1.9-fold, whereas its AUC0-∞ increased 1.3-fold. The sorafenib N-oxide Cmax increased 1.9-fold whereas its AUC0-∞ increased 1.3-fold. The sorafenib N-oxide/SR AUC0–t ratio increased 1.4-fold (p = 0.0127).

The results show that the co-administration of sorafenib and tapentadol increases the exposure to both drugs and changes their metabolism. In consequence, the pharmacological effect may be intensified, but the toxicity may increases, too.

Comments

This article is published as Karbownik, Agnieszka, Miłosz Miedziaszczyk, Tomasz Grabowski, Joanna Stanisławiak-Rudowicz, Radosław Jaźwiec, Anna Wolc, Edmund Grześkowiak, and Edyta Szałek. "In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol." Biomedicine & Pharmacotherapy 130 (2020): 110530. doi: 10.1016/j.biopha.2020.110530.

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Copyright Owner

Published by Elsevier Masson SAS

Language

en

File Format

application/pdf

Share

COinS